Bausch Health Companies Inc. Stock
$4.55
0.87%
yesterday
NYSE,
May 28, 10:00 pm CET
Bausch Health Companies Inc. Stock price
$4.55
-0.86
15.90%
1M
-3.57
43.97%
6M
-3.51
43.55%
YTD
-1.65
26.61%
1Y
-5.32
53.90%
3Y
-14.03
75.51%
5Y
-237.18
98.12%
10Y
NYSE,
Closing price Wed, May 28 2025
-0.04
0.87%
Powered by
ISIN
CA0717341071
Symbol
BHC
Index
Sector
Industry
Key metrics
| Market capitalization | $1.67b |
| Enterprise Value | $22.04b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 18.13 |
| EV/Sales (TTM) EV/Sales | 2.27 |
| P/S ratio (TTM) P/S ratio | 0.17 |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue growth (TTM) Revenue growth | 8.53% |
| Revenue (TTM) Revenue | $9.73b |
Show more
Is Bausch Health Companies Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
Bausch Health Companies Inc. Stock Analysis
Unlock Scores for Free
Analyst Opinions
6 Analysts have issued a Bausch Health Companies Inc. forecast:
Analyst Opinions
6 Analysts have issued a Bausch Health Companies Inc. forecast:
Hold
83%
Sell
17%
Financial data from Bausch Health Companies Inc.
| Mar '25 |
+/-
%
|
||
| Revenue | 9,731 9,731 |
9%
9%
|
|
| Gross Profit | 6,888 6,888 |
8%
8%
|
|
| EBITDA | 2,911 2,911 |
6%
6%
|
EBIT (Operating Income) EBIT | 1,852 1,852 |
11%
11%
|
| Net Profit | -40 -40 |
91%
91%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Bausch Health Companies Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bausch Health Companies Inc. Stock News
Neutral
GlobeNewsWire
●
7 days ago
The facial injectable market is poised for significant growth, with a rise from US$18.310 billion in 2025 to US$32.083 billion by 2030, driven by an 11.87% CAGR. Increasing emphasis on physical appearance and the popularity of minimally invasive procedures fuel demand, while the Asia-Pacific region sees rapid expansion due to urbanization and rising incomes. Key players like Allergan and Galder...
Neutral
Business Wire
●
8 days ago
Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY Preservative Free redness reliever eye drops, the first and only preservative-free over-the-counter eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye d...
Neutral
Accesswire
●
14 days ago
LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual Meeting") held on May 13, 2025. The detailed results of the vote for the election of directors are set out below: Name For Withheld Broker Non-Votes Thomas J.
Company Profile
Manufactures and markets pharmaceutical products
| Head office | Canada |
| CEO | Thomas Appio |
| Employees | 20,700 |
| Founded | 1994 |
| Website | www.bauschhealth.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
